Alpha-Synuclein Genetics in Parkinson's Disease

The SNCA gene, responsible for encoding the presynaptic protein alpha-synuclein, occupies a central role in the genetic architecture of Parkinson’s disease. Pathogenic variations in SNCA, including point substitutions such as A30P and A53T, along with gene duplications and triplications, drive a dosage-dependent cascade of misfolding, aggregation and insoluble fibril formation. These aberrant species accumulate as Lewy bodies within dopaminergic neurons of the substantia nigra, disrupting synaptic vesicle recycling, mitochondrial dynamics and protein clearance pathways. Both rare monogenic mutations and common risk alleles at the SNCA locus contribute to a spectrum of clinical phenotypes, ranging from early-onset familial parkinsonism to sporadic late-onset disease. Population genetics studies underscore regional variability in variant frequency, emphasising the need for diverse cohorts. Advances in high-resolution sequencing and structural biology have illuminated the conformational landscape of alpha-synuclein, informing biomarker discovery and spurring the development of targeted therapies to mitigate neurodegeneration.

Research from Nature Portfolio

Evolutionary and structural analyses of SNCA across diverse vertebrate species have identified a strongly conserved lipid-binding N-terminal domain, particularly residues 32–58, as a pivotal determinant of alpha-synuclein conformational stability. Computational modelling revealed that lineage-specific substitutions modulate the epistatic network governing helix formation, while purifying selection underscores functional constraints in this region. These findings refine understanding of aggregation-prone interfaces and pinpoint conserved structural hotspots that may serve as targets for aggregation inhibitors.

Alpha-Synuclein Genetics in Parkinson's Disease publication trend

The graph below shows the total number of articles in alpha-synuclein genetics in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

SNCA: The gene encoding alpha-synuclein, whose variations include point mutations and multiplications associated with Parkinson’s disease.

Alpha-synuclein: A presynaptic neuronal protein prone to misfolding and aggregation, forming Lewy bodies characteristic of Parkinson’s disease.

Missense mutation: A single nucleotide change in the SNCA gene resulting in an amino acid substitution that can alter protein folding and aggregation propensity.

Gene multiplications: Duplication or triplication of the SNCA locus that leads to increased alpha-synuclein expression and dosage-dependent neurotoxicity.

Lewy body: Intracellular inclusion composed primarily of aggregated alpha-synuclein, serving as a pathological hallmark of Parkinson’s disease.

Epistasis: Interaction between genes whereby variant effects at one locus modulate the phenotypic impact of variants at another locus.

References

1. Alpha‐Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Parkinson's Disease (2016).
2. Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles. Molecular Neurodegeneration (2019).
3. The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication. Scientific Reports (2016).
4. Resequencing the complete SNCA locus in Indian patients with Parkinson’s disease. npj Parkinson's Disease (2024).
5. Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease. Molecular Neurodegeneration (2023).
6. Increased Levels of the Parkinson’s Disease-Associated Gene ITPKB Correlate with Higher Expression Levels of α-Synuclein, Independent of Mutation Status. International Journal of Molecular Sciences (2023).